http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
RF 및 DC 마그네트론 스퍼터링 방법으로 성막된 Al2O3-doped ZnO 박막의 특성 연구
장덕우,김화민,고현규,김종재,박승환,양정민,이병로,하재영,홍우표 한국물리학회 2007 새물리 Vol.55 No.5
The electric and the optical properties of Al$_2$O$_3$-doped ZnO films (AZO) grown by RF and DC magnetron sputtering were studied as functions of the sputtering power, the film thickness, and the post-annealing treatment. Films were grown on glass by using an Al$_2$O$_3$ (2 wt\%)-doped ZnO target at room temperature. Films grown under optimal conditions showed a resistivity of 1.3 $\times$ 10$^{-3}$ $\Omega$.cm and a transmittance of 81 \% for an applied RF power of 130 W and a film thickness of 500 nm. The electrical and the optical properties of the Al$_2$O$_3$-doped ZnO films were observed to be nearly independent of the post-annealing treatment, showing the thermal stability of the AZO films. RF 및 DC 마그네트론 스퍼터링 방법으로 2 wt\% 의 Al$_2$O$_3$가 첨가된 ZnO 타겟 (AZO)을 이용하여 유리기판 위에 투명 전도막을 상온 증착하여, 스퍼터 전력, 박막 두께 그리고 후열처리에 따른 전기적ㆍ광학적 특성을 조사하였다. RF 전력 130 W, 두께 500 nm의 AZO 박막에서 비저항 1.3 $\times$ 10$^{-3}$ $\Omega$cm, 광투과도 81 \%의 특성이 나타났다. 그리고 후열처리에 따른 비저항과 광투과도는 거의 변화가 없으며, 이는 AZO 박막이 500 $^\circ$C이하에서 매우 안정적임을 보여주는 것이다.
3D8 ScFv 형질전환 닭의 항-바이러스성 기능 검증
장예진,지미란,전미향,김점순,정학재,한덕우,김경운,김동훈,양병철,박춘근,류재규,박진기,변승준 한국동물번식학회 2012 Reproductive & Developmental Biology(Supplement) Vol.36 No.2s
본 연구는 핵산가수분해 기능이 있는 항체인 3D8 scFv(single-chain variable fragment) 유전자를 형질전환 닭에서 발현시키고 3D8 scFv 항체의 항-바이러스 기능을 검증하고자 한다. 연구는 in vitro(형질전환 닭유래 세포)와 in vivo(형질전환 닭)로 나누어서 수행하고자 한다. 먼저 닭 태아섬유아세포는 형질전환 닭과 일반 닭을 각각 인공수정을 시킨 후 생산된 10일차 수정란의 태아에서 CEF(Chicken Embryo Fibroblast)를 수집하였다. 3D8 scFv 유전 자가 삽입된 CEF 세포는 항생제(puromycin)를 이용하여 형질전환 세포만을 선발하였다. 그 리고 선발된 CEF 세포는 면역염색을 이용하여 3D8 scFv 유전자가 세포내에서 단백질로 발현됨을 확인하였다. 그리고 선발된 세포들의 항-바이러스 기능 검증은 GFP 유전자로 표 지된 재조합 NDV(Newcastle Disease Virus)를 세포에 직접 감염시키고, 세포내에서 발현 하 는 GFP의 발현량을 FACS를 이용하여 정량하는 방법으로 항-바이러스 기능을 조사하였다. 이들 가운데 항-바이러스 기능이 있을 것으로 예상되는 형질전환 2계통에 대하여 항-바이러스 기능을 검증을 준비하고 있다.
3D8 ScFv 형질전환 닭의 항-바이러스성 기능 검증
장예진,지미란,전미향,김점순,정학재,한덕우,김경운,김동훈,양병철,박춘근,류재규,박진기,변승준 한국동물번식학회 2012 Reproductive & developmental biology Vol.36 No.2
본 연구는 핵산가수분해 기능이 있는 항체인 3D8 scFv(single-chain variable fragment) 유전자를 형질전환 닭에서 발현시키고 3D8 scFv 항체의 항-바이러스 기능을 검증하고자 한다. 연구는 in vitro(형질전환 닭유래 세포)와 in vivo(형질전환 닭)로 나누어서 수행하고자 한다. 먼저 닭 태아섬유아세포는 형질전환 닭과 일반 닭을 각각 인공수정을 시킨 후 생산된 10일차 수정란의 태아에서 CEF(Chicken Embryo Fibroblast)를 수집하였다. 3D8 scFv 유전 자가 삽입된 CEF 세포는 항생제(puromycin)를 이용하여 형질전환 세포만을 선발하였다. 그 리고 선발된 CEF 세포는 면역염색을 이용하여 3D8 scFv 유전자가 세포내에서 단백질로 발현됨을 확인하였다. 그리고 선발된 세포들의 항-바이러스 기능 검증은 GFP 유전자로 표 지된 재조합 NDV(Newcastle Disease Virus)를 세포에 직접 감염시키고, 세포내에서 발현 하 는 GFP의 발현량을 FACS를 이용하여 정량하는 방법으로 항-바이러스 기능을 조사하였다. 이들 가운데 항-바이러스 기능이 있을 것으로 예상되는 형질전환 2계통에 대하여 항-바이러스 기능을 검증을 준비하고 있다.
장재식,한규록,문건웅,전동운,신동호,김정선,박덕우,강현재,김주한,배장환,허승호,김병옥,최동훈,권현철,김효수 대한심장학회 2017 Korean Circulation Journal Vol.47 No.3
Background and Objectives: Although several multicenter registries have evaluated percutaneous coronary intervention (PCI) procedures in Korea, those databases have been limited by non-standardized data collection and lack of uniform reporting methods. We aimed to collect and report data from a standardized database to analyze PCI procedures throughout the country. Materials and Methods: Both clinical and procedural data, as well as clinical outcomes data during hospital stay, were collected based on case report forms that used a standard set of 54 data elements. This report is based on 2014 Korean PCI registry cohort data. Results: A total of 92 hospitals offered data on 44967 PCI procedures. The median age was 66.0 interquartile range 57.0-74.0 years, and 70.3% were men. Thirty-eight percent of patients presented with acute myocardial infarction and one-third of all PCI procedures were performed in an urgent or emergency setting. Non-invasive stress tests were performed in 13.9% of cases, while coronary computed tomography angiography was used in 13.7% of cases prior to PCI. Radial artery access was used in 56.1% of all PCI procedures. Devices that used PCI included drug-eluting stent, plain old balloon angioplasty, drug-eluting balloon, and bare-metal stent (around 91%, 19%, 6%, and 1% of all procedures, respectively). The incidences of in-hospital death, non-fatal myocardial infarction, and stroke were 2.3%, 1.6%, and 0.2%, respectively. Conclusion: These data may provide an overview of the current PCI practices and in-hospital outcomes in Korea and could be used as a foundation for developing treatment guidelines and nationwide clinical research.
장예진,지미란,전미향,김점순,김경운,한덕우,정학재,양병철,류재규,박진기,김태완,변승준 韓國家禽學會 2012 韓國家禽學會誌 Vol.39 No.3
본 연구는 형질전환 닭에서 주입한 외래 유전자의 세대간 전이와 발현 양상을 조사하고자 하였다. 외래 유전자 전이 양상 조사는 제3세대(G2) GFP 형질전환 수탉을 최초 부계로 사용하여 최종적으로 제9세대(G8) 형질전환 닭을 연속적으로 생산하면서 GFP 유전자 전이 양상을 조사하였다. 형질 전환 병아리 유전 분석은 자외선 램프 아래에서 부화한 병아리들의 날개, 부리와 다리에서 녹색형광단백질을 발현하는 병아리들만을 형질전환으로 선발하였다. 형질전환 닭에서 외래 유전자 전이율은 대략 38~58%이었다. 이는 유전자 전이가 멘델의 유전 법칙을 따르고 있음을 보여주고 있다. 연구결과는 GFP 유전자가 유전자 침묵 없이 멘델의 유전 법칙에 따라 다음 세대로 계속 전이와 발현된다는 것을 보여 주고 있다. This study was performed to analyze the generational transmission and the expression of the foreign gene in the GFP transgenic chickens. The transmission rate and the expression of the GFP gene was investigated from the GFP transgenic rooster (G2) as the first founder to the ninth (G8). Analysis of GFP expression in hatched chickens was used the UV lamp. When GFP was expressed in the wings, bill and legs of a chick, the bird only was selected as a transgenic chick. The average transmission rate of the overall transgenic was 38~58%. These results showed that the transmission of the GFP gene in the transgenic chickens in accordance with the laws of Mendel's continues to the next generation without gene silencing.
황인성,장덕우,김규동,이승훈,한천구 대한건축학회 2003 대한건축학회 학술발표대회 논문집 - 계획계/구조계 Vol.23 No.2
This study is intended to develop AE water reducing agent for reduction of bleeding and investigate its practical use. According to the results, fluidity and air content increases with an increase of superplasticizer and MC viscosity agent, AE water reducing agent for reduction of bleeding is developed after determining the ratio of superplasticizer and MC viscosity agent as 3:1 to satisfy the same fluidity and air content to conventional concrete and reduce bleeding amount. As the adding ratio of developed AE water reducing agent for reduction of bleeding increases, fluidity also increases, air content satisfies the aimed range, bleeding and sinking amount of concrete are reduced, and compressive strength is almost not different from plain concrete. Therefore, developed AE water reducing agent for reduction of bleeding satisfies the aimed air content in the range of slump 12~21cm, and can also reduce bleeding amount effectively without quality deterioration of compressive strength.
Bioresorbable Vascular Scaffold Korean Expert Panel Report
안정민,박덕우,홍성진,안영근,한주용,김원장,홍순준,남창욱,강도윤,이승률,천우정,허정호,조덕규,김진원,허성호,김상욱,유상용,홍명기,탁승제,김기식,김무현,장양수,박승정 대한심장학회 2017 Korean Circulation Journal Vol.47 No.6
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management
권현철,전동운,강현재,장재식,박덕우,신동호,문건웅,김정선,김주한,배장환,허승호,김병옥,최동훈,한규록,김효수 대한심장학회 2017 Korean Circulation Journal Vol.47 No.3
Background and Objectives: Appropriate use criteria (AUC) was developed to improve the quality of percutaneous coronary intervention (PCI). However, these criteria should consider the current practice pattern in the country where they are being applied. Materials and Methods: The algorithm for the Korean PCI practice pattern (KP3) was developed by modifying the United States-derived AUC in expert consensus meetings. KP3 class A was defined as any strategy with evidence from randomized trials that was more conservative for PCI than medical therapy or coronary artery bypass graft (CABG). Class C was defined as any strategy with less evidence from randomized trials and more aggressive for PCI than medical therapy or CABG. Class B was defined as a strategy that was partly class A and partly class C. We applied the KP3 classification system to the Korean PCI registry. Results: The KP3 class A was noted in 67.7% of patients, class B in 28.8%, and class C in 3.5%. The median proportion of class C cases per center was 2.0%. The distribution of KP3 classes varied significantly depending on clinical and angiographic characteristics. The proportion of KP3 class C cases per center was not significantly dependent on PCI volume, but rather on the percentage of ACS cases in each center. Conclusion: We report the current PCI practice pattern by applying the new KP3 classification in a nationwide PCI registry. The results should be interpreted carefully with due regard for the complex relationships between the determining variables and the healthcare system in Korea.